PALMITIC MONOETHANOLAMIDE
Migraine
RDC Clinical Pty LtdSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
106 Active assets in the Migraine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atogepant Stanford University | Phase 4 | A |
Naproxen IRCCS San Raffaele Roma | Phase 4 | A |
Rizatriptan Antonios Likourezos | Phase 4 | A |
Zolmitriptan Zosano Pharma Corporation | Phase 4 | A |
mk-1602 H. Lundbeck A/S | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
PALMITIC MONOETHANOLAMIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →